RPS: Brexit poses counterfeit medicines risk as FMD benefits lost
The government must put “robust plans” in place to ensure counterfeit medicines don’t enter the supply chain as FMD ceases to apply across the UK post Brexit, the RPS has said.
The government must put “robust plans” in place to ensure counterfeit medicines don’t enter the supply chain as FMD ceases to apply across the UK post Brexit, the RPS has said.